Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir

TAGS

Divi’s Laboratories Limited has been selected by pharma giant MSD (known as in the US and Canada) as an authorized manufacturer for the active pharmaceutical ingredient (API) of the latter drug candidate Molnupiravir.

The Hyderabad-based API producer said that it is allowed to supply API to ’s

Currently, is being evaluated in a phase 3 clinical trial. is developing the drug candidate in collaboration with Ridgeback Biotherapeutics.

Divi's Laboratories to manufacture API of MSD’s Covid drug Molnupiravir

Divi’s Laboratories to manufacture API of ’s Covid drug Molnupiravir. Image courtesy of Pete Linforth from Pixabay.

Last month, Cipla signed a non-exclusive licensing agreement with MSD for the manufacturing and distribution of for the treatment of non-hospitalized patients.

CATEGORIES
TAGS
Share This